Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-25-109824
Filing Date
2025-08-18
Accepted
2025-08-18 17:08:53
Documents
2
Period of Report
2025-08-11

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 1629
2 EX-24 bbot-ex24.htm EX-24 21916
  Complete submission text file 0000950170-25-109824.txt   25106
Mailing Address 256 E. GRAND AVENUE, SUITE 104 SOUTH SAN FRANCISCO CA 94080
Business Address 256 E. GRAND AVENUE, SUITE 104 SOUTH SAN FRANCISCO CA 94080 857 702 0377
BridgeBio Oncology Therapeutics, Inc. (Issuer) CIK: 0001869105 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O THERAS, INC. 3160 PORTER DRIVE SUITE 250 PALO ALTO CA 94304
Business Address
Mehra Uneek (Reporting) CIK: 0001881504 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-41955 | Film No.: 251228770